$阿玛琳(AMRN)$ • The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on Thursday, November 14, to review and discuss Amarin's (NASDAQ:AMRN) supplemental marketing application seeking a cardiovascular (CV) benefit claim for Vascepa (icosapent ethyl).